HLN Stock Overview
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Haleon plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£8.26 |
| 52 Week High | UK£8.96 |
| 52 Week Low | UK£7.70 |
| Beta | 0 |
| 11 Month Change | -2.13% |
| 3 Month Change | -0.96% |
| 1 Year Change | -1.43% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.13% |
Recent News & Updates
Recent updates
The Investment Case For Haleon: Steady Shareholder Value Accumulation
Nov 20The Share Price Has The Flu, But Haleon Is As Healthy As An Ox
Sep 07Haleon: A Hidden Gem In The Consumer Health Market
Jun 12Haleon exploring sale of ChapStick Brand - report
Feb 25Haleon said to evaluate potential deals to increase its size - report
Jan 31Haleon: Undervalued With Clear Catalyst Ahead
Aug 31Former GSK consumer health unit Haleon hits all-time low
Aug 19Haleon CEO says brand recognition, gross margins will drive growth - CNBC
Jul 20Shareholder Returns
| HLN | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -3.6% | -1.5% | 0.07% |
| 1Y | -1.4% | -29.3% | 20.7% |
Return vs Industry: HLN exceeded the US Personal Products industry which returned -30.2% over the past year.
Return vs Market: HLN underperformed the US Market which returned 20.7% over the past year.
Price Volatility
| HLN volatility | |
|---|---|
| HLN Average Weekly Movement | 2.2% |
| Personal Products Industry Average Movement | 8.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HLN has not had significant price volatility in the past 3 months.
Volatility Over Time: HLN's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 25,408 | Brian McNamara | www.haleon.com |
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.
Haleon plc Fundamentals Summary
| HLN fundamental statistics | |
|---|---|
| Market cap | US$37.24b |
| Earnings (TTM) | US$1.37b |
| Revenue (TTM) | US$14.20b |
27.2x
P/E Ratio2.6x
P/S RatioIs HLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLN income statement (TTM) | |
|---|---|
| Revenue | UK£11.24b |
| Cost of Revenue | UK£4.28b |
| Gross Profit | UK£6.96b |
| Other Expenses | UK£5.88b |
| Earnings | UK£1.08b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 61.94% |
| Net Profit Margin | 9.64% |
| Debt/Equity Ratio | 57.4% |
How did HLN perform over the long term?
See historical performance and comparison